>Core business momentum remains soft on overprovision reversals - Sales increased 22% y-o-y in Q3 2024 (vs -7% in Q2, +12% in Q1 and -20% in Q4). Biopharma sales decreased 5% y-o-y in Q3 2024 (compared to -18% in Q2, +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect, 9M 2024 Lurbi sales in Europe are growing at a +14% pace (vs +16% in H1). Royalties post...
>Headline momentum appears weak but Lurbi keeps growing in underlying terms - Sales decreased 7% y-o-y in Q2 2024 (vs +12% in Q1 and -20% in Q4). Biopharma sales decreased 18% y-o-y in Q2 2024 (compared to +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect H1 2024 Lurbi sales in Europe is growing at a +16% pace. Royalties posted a +18% y-o-y increase (vs ...
>Feedback from 52 companies present on day three - Our 13th edition of the ODDO BHF Nextcap Forum takes place on June 4 and 5 in Paris, and on June 6 virtually. Following the third day, which took place yesterday virtually at our Paris office with 52 companies in attendance, we publish hereafter feedback for those companies present:Aedas HomesLhyfeAfyrenMaisons Du MondeAltamirMcPhy EnergyAltriMister SpexAtresmediaNein...
>Feedback de 52 sociétés présentes le 3ème jour - Notre 13ème édition du ODDO BHF Nextcap Forum a lieu les 4 et 5 juin en physique à Paris et le 6 juin en virtuel. Suite à la troisième journée qui a eu lieu hier en virtuel avec 53 de sociétés présentes, nous publions ci-après un feedback pour chacune des sociétés couvertes :Aedas HomesLhyfeAfyrenMaisons Du MondeAltamirMcphy EnergyAltriMister SpexAtresmediaNeinor Homes§...
>Oncology gains momentum - Sales grew +12% y-o-y in Q1 2024 (vs -20% in Q4 and -9% in Q3). Biopharma sales increased +25% y-o-y in Q1 2024 (compared to -32% in Q4 and -27% in Q3) namely owing to higher revenues from Zepzelca and, to a lesser extent, also higher raw material and ‘early access’ sales. Royalties posted a +14% y-o-y increase (vs -6% in Q4 and+20% in Q3) while the more erratic licence revenues declined -8% which nonetheless implies a material sequential im...
>Higher royalties offset the anticipated oncology slowdown - Total revenues receded significantly -20% y-o-y in Q4 2023 (vs -9% in Q3 and -1% in Q2), yet they were above our estimate helped by higher-than-expected royalties and licences (€ 29m vs € 20m est.). Biopharma sales decreased -32% y-o-y in Q4 2023 (compared to -27% in Q3 and -2% in Q2) reflecting a normalisation after the inflated figures seen in previous quarters that were favoured by one-off ‘early-access...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.